Chlorzoxazone is a pharmaceutical ingredient whose molecular pharmacology encompasses primary target interactions, off-target binding to safety-relevant proteins, and concentration-response relationships that collectively determine whether pharmacologically-based or NOAEL-based OEL derivation methodology is more protective for occupationally exposed workers. The identification of the critical pharmacodynamic effect and its dose-response threshold in humans—from clinical pharmacology studies or clinical pharmacokinetic-pharmacodynamic modelling—provides a scientifically superior basis for OEL derivation compared to default interspecies extrapolation from animal toxicity data.
Health-based exposure limits for Chlorzoxazone require formal periodic review as new toxicological evidence, clinical safety data, or regulatory agency assessments become available. Pharmaceutical manufacturers are expected to maintain a defined review cycle—typically every 3–5 years or triggered by significant new findings—and to update OEL, PDE,
